These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30362288)

  • 41. Prophylactic efficacy and pharmacokinetically guided dosing of a von Willebrand factor/factor VIII concentrate in adults and children with von Willebrand's disease undergoing elective surgery: a pooled and comparative analysis of data from USA and European Union clinical trials.
    Mannuccio Mannucci P; Kyrle PA; Schulman S; Di Paola J; Schneppenheim R; Cox Gill J
    Blood Transfus; 2013 Oct; 11(4):533-40. PubMed ID: 23736911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant factor VIII Fc fusion protein: extended-interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels.
    Shapiro AD; Ragni MV; Kulkarni R; Oldenberg J; Srivastava A; Quon DV; Pasi KJ; Hanabusa H; Pabinger I; Mahlangu J; Fogarty P; Lillicrap D; Kulke S; Potts J; Neelakantan S; Nestorov I; Li S; Dumont JA; Jiang H; Brennan A; Pierce GF
    J Thromb Haemost; 2014 Nov; 12(11):1788-800. PubMed ID: 25196897
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi) in the treatment of von Willebrand disease: a retrospective clinical study.
    Federici AB; Baudo F; Caracciolo C; Mancuso G; Mazzucconi MG; Musso R; Schinco PC; Targhetta R; Mannuccio Mannucci P
    Haemophilia; 2002 Nov; 8(6):761-7. PubMed ID: 12410644
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.
    Federici AB; Castaman G; Franchini M; Morfini M; Zanon E; Coppola A; Tagliaferri A; Boeri E; Mazzucconi MG; Rossetti G; Mannucci PM
    Haematologica; 2007 Jul; 92(7):944-51. PubMed ID: 17606445
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics, efficacy, and safety of a plasma-derived VWF/FVIII concentrate (VONCENTO) for on-demand and prophylactic treatment in patients with von Willebrand disease (SWIFT-VWD study).
    Lissitchkov TJ; Buevich E; Kuliczkowski K; Stasyshyn O; Cerqueira MH; Klukowska A; Joch C; Seifert W
    Blood Coagul Fibrinolysis; 2017 Mar; 28(2):152-162. PubMed ID: 27203734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
    Bello IF; Yuste VJ; Molina MQ; Navarro FH
    Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Structure and function of a recombinant von Willebrand factor drug candidate.
    Turecek PL; Schrenk G; Rottensteiner H; Varadi K; Bevers E; Lenting P; Ilk N; Sleytr UB; Ehrlich HJ; Schwarz HP
    Semin Thromb Hemost; 2010 Jul; 36(5):510-21. PubMed ID: 20635317
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease.
    Gritsch H; Schrenk G; Weinhappl N; Mellgård B; Ewenstein B; Turecek PL
    J Blood Med; 2022; 13():649-662. PubMed ID: 36405429
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
    Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
    Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease.
    Ver Elst KM; van Vliet HD; Kappers-Klunne MC; Leebeek FW
    Thromb Haemost; 2004 Jul; 92(1):67-74. PubMed ID: 15213847
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Factor VIII-mediated global hemostasis in the absence of von Willebrand factor.
    Takeyama M; Kasuda S; Sakurai Y; Shima M; Takeda T; Omura S; Naka H; Yoshioka A
    Int J Hematol; 2007 Jun; 85(5):397-402. PubMed ID: 17562614
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Perioperative management for patients with von Willebrand disease: Defining the optimal approach.
    Miesbach W
    Eur J Haematol; 2020 Oct; 105(4):365-377. PubMed ID: 32496614
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
    Auerswald G; Kreuz W
    Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Progress in the treatment of bleeding disorders.
    Bergman GE
    Thromb Res; 2011 Jan; 127 Suppl 1():S3-5. PubMed ID: 21035836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease.
    Peyvandi F; Castaman G; Gresele P; De Cristofaro R; Schinco P; Bertomoro A; Morfini M; Gamba G; Barillari G; Jiménez-Yuste V; Königs C; Iorio A; Federici AB
    Blood Transfus; 2019 Sep; 17(5):391-398. PubMed ID: 30747707
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.